替西多单抗（LFG316）用于治疗阵发性睡眠性血红蛋白尿症的C5变异型患者。 - Suppr

Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria.

作者信息

Nishimura Jun-Ichi, Ando Kiyoshi, Masuko Masayoshi, Noji Hideyoshi, Ito Yoshikazu, Mayer Jiri, Griskevicius Laimonas, Bucher Christoph, Müllershausen Florian, Gergely Peter, Rozenberg Izabela, Schubart Anna, Chawla Raghav, Rondeau Jean-Michel, Roguska Michael, Splawski Igor, Keating Mark T, Johnson Leslie, Danekula Rambabu, Bagger Morten, Watanabe Yoko, Haraldsson Börje, Kanakura Yuzuru

机构信息

Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita.

Department of Hematology and Oncology, Tokai University, Isehara.

出版信息

Haematologica. 2022 Jun 1;107(6):1483-1488. doi: 10.3324/haematol.2020.265868.

DOI:10.3324/haematol.2020.265868

PMID:35263983

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9152970/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f510/9152970/8002feb2fb82/1071483.fig1.jpg

相似文献

Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria.

Haematologica. 2022 Jun 1;107(6):1483-1488. doi: 10.3324/haematol.2020.265868.

Paroxysmal nocturnal hemoglobinuria turning Coombs-positive.

Int J Hematol. 2010 Mar;91(2):159-60. doi: 10.1007/s12185-010-0493-0. Epub 2010 Feb 9.

Eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.

Clin Adv Hematol Oncol. 2005 Nov;3(11):849-50.

[Paroxysmal nocturnal hemoglobinuria].

Rev Med Interne. 2008 Nov;29(11):957-61. doi: 10.1016/j.revmed.2008.08.001. Epub 2008 Sep 17.

Pegcetacoplan for paroxysmal nocturnal hemoglobinuria.

Blood. 2022 Jun 9;139(23):3361-3365. doi: 10.1182/blood.2021014868.

Life-threatening desquamating rash and hyperammonemia following administration of eculizumab for paroxysmal nocturnal hemoglobinuria.

Am J Hematol. 2008 Nov;83(11):881-3. doi: 10.1002/ajh.21265.

Paroxysmal nocturnal hemoglobinuria--hemolysis before and after eculizumab.

N Engl J Med. 2010 Dec 2;363(23):2270-2. doi: 10.1056/NEJMc1010351.

Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria.

Expert Rev Hematol. 2009 Feb;2(1):7-16. doi: 10.1586/17474086.2.1.7.

Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.

Haematologica. 2010 Apr;95(4):567-73. doi: 10.3324/haematol.2009.007229. Epub 2010 Feb 9.

[Evidence of the efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria].

Rev Med Suisse. 2006 Oct 4;2(81):2255.

引用本文的文献

[Advances in complement inhibition therapy for paroxysmal nocturnal hemoglobinuria].

Zhonghua Xue Ye Xue Za Zhi. 2025 Jan 14;46(1):90-96. doi: 10.3760/cma.j.cn121090-20240903-00332.

The Complement System as a Therapeutic Target in Retinal Disease.

Medicina (Kaunas). 2024 Jun 5;60(6):945. doi: 10.3390/medicina60060945.

Safety Profile of Monoclonal Antibodies and Subsequent Drug Developments in the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

Medicina (Kaunas). 2024 Feb 24;60(3):379. doi: 10.3390/medicina60030379.

Paroxysmal Nocturnal Hemoglobinuria: Current Management, Unmet Needs, and Recommendations.

J Blood Med. 2023 Dec 6;14:613-628. doi: 10.2147/JBM.S431493. eCollection 2023.

本文引用的文献

Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria.

Expert Opin Biol Ther. 2020 Mar;20(3):227-237. doi: 10.1080/14712598.2020.1725468. Epub 2020 Feb 14.

Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.

Blood. 2019 Feb 7;133(6):530-539. doi: 10.1182/blood-2018-09-876136. Epub 2018 Dec 3.

Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan.

Int J Hematol. 2018 Jun;107(6):656-665. doi: 10.1007/s12185-018-2409-3. Epub 2018 Jan 30.

Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.

Immunobiology. 2017 Feb;222(2):363-371. doi: 10.1016/j.imbio.2016.09.002. Epub 2016 Sep 13.

Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review.

Eur J Haematol. 2015 Sep;95(3):190-8. doi: 10.1111/ejh.12543. Epub 2015 Mar 26.

Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria.

Cochrane Database Syst Rev. 2014 Oct 30(10):CD010340. doi: 10.1002/14651858.CD010340.pub2.

Paroxysmal nocturnal hemoglobinuria.

Blood. 2014 Oct 30;124(18):2804-11. doi: 10.1182/blood-2014-02-522128. Epub 2014 Sep 18.

Genetic variants in C5 and poor response to eculizumab.

N Engl J Med. 2014 Feb 13;370(7):632-9. doi: 10.1056/NEJMoa1311084.

Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab.

Blood. 2009 Apr 23;113(17):4094-100. doi: 10.1182/blood-2008-11-189944. Epub 2009 Jan 29.

Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.

Blood. 2007 Dec 1;110(12):4123-8. doi: 10.1182/blood-2007-06-095646. Epub 2007 Aug 16.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria.

作者信息

机构信息

Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita.

Department of Hematology and Oncology, Tokai University, Isehara.

出版信息

Haematologica. 2022 Jun 1;107(6):1483-1488. doi: 10.3324/haematol.2020.265868.

DOI:10.3324/haematol.2020.265868

PMID:35263983

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9152970/

Abstract

摘要

相似文献

Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria.

Haematologica. 2022 Jun 1;107(6):1483-1488. doi: 10.3324/haematol.2020.265868.

Paroxysmal nocturnal hemoglobinuria turning Coombs-positive.

Int J Hematol. 2010 Mar;91(2):159-60. doi: 10.1007/s12185-010-0493-0. Epub 2010 Feb 9.

Eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.

Clin Adv Hematol Oncol. 2005 Nov;3(11):849-50.

[Paroxysmal nocturnal hemoglobinuria].

Rev Med Interne. 2008 Nov;29(11):957-61. doi: 10.1016/j.revmed.2008.08.001. Epub 2008 Sep 17.

Pegcetacoplan for paroxysmal nocturnal hemoglobinuria.

Blood. 2022 Jun 9;139(23):3361-3365. doi: 10.1182/blood.2021014868.

Life-threatening desquamating rash and hyperammonemia following administration of eculizumab for paroxysmal nocturnal hemoglobinuria.

Am J Hematol. 2008 Nov;83(11):881-3. doi: 10.1002/ajh.21265.

Paroxysmal nocturnal hemoglobinuria--hemolysis before and after eculizumab.

N Engl J Med. 2010 Dec 2;363(23):2270-2. doi: 10.1056/NEJMc1010351.

Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria.

Expert Rev Hematol. 2009 Feb;2(1):7-16. doi: 10.1586/17474086.2.1.7.

Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.

Haematologica. 2010 Apr;95(4):567-73. doi: 10.3324/haematol.2009.007229. Epub 2010 Feb 9.

[Evidence of the efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria].

Rev Med Suisse. 2006 Oct 4;2(81):2255.

引用本文的文献

[Advances in complement inhibition therapy for paroxysmal nocturnal hemoglobinuria].

Zhonghua Xue Ye Xue Za Zhi. 2025 Jan 14;46(1):90-96. doi: 10.3760/cma.j.cn121090-20240903-00332.

The Complement System as a Therapeutic Target in Retinal Disease.

Medicina (Kaunas). 2024 Jun 5;60(6):945. doi: 10.3390/medicina60060945.

Safety Profile of Monoclonal Antibodies and Subsequent Drug Developments in the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

Medicina (Kaunas). 2024 Feb 24;60(3):379. doi: 10.3390/medicina60030379.

Paroxysmal Nocturnal Hemoglobinuria: Current Management, Unmet Needs, and Recommendations.

J Blood Med. 2023 Dec 6;14:613-628. doi: 10.2147/JBM.S431493. eCollection 2023.

本文引用的文献

Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria.

Expert Opin Biol Ther. 2020 Mar;20(3):227-237. doi: 10.1080/14712598.2020.1725468. Epub 2020 Feb 14.

Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.

Blood. 2019 Feb 7;133(6):530-539. doi: 10.1182/blood-2018-09-876136. Epub 2018 Dec 3.

Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan.

Int J Hematol. 2018 Jun;107(6):656-665. doi: 10.1007/s12185-018-2409-3. Epub 2018 Jan 30.

Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.

Immunobiology. 2017 Feb;222(2):363-371. doi: 10.1016/j.imbio.2016.09.002. Epub 2016 Sep 13.

Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review.

Eur J Haematol. 2015 Sep;95(3):190-8. doi: 10.1111/ejh.12543. Epub 2015 Mar 26.

Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria.

Cochrane Database Syst Rev. 2014 Oct 30(10):CD010340. doi: 10.1002/14651858.CD010340.pub2.

Paroxysmal nocturnal hemoglobinuria.

Blood. 2014 Oct 30;124(18):2804-11. doi: 10.1182/blood-2014-02-522128. Epub 2014 Sep 18.

Genetic variants in C5 and poor response to eculizumab.

N Engl J Med. 2014 Feb 13;370(7):632-9. doi: 10.1056/NEJMoa1311084.

Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab.

Blood. 2009 Apr 23;113(17):4094-100. doi: 10.1182/blood-2008-11-189944. Epub 2009 Jan 29.

Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.

Blood. 2007 Dec 1;110(12):4123-8. doi: 10.1182/blood-2007-06-095646. Epub 2007 Aug 16.

Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献